Artivion, Inc. AORT
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -50.49%
- 1 year
- -50.54%
- Open
- 23.62
- Prev close
- 23.44
- Mkt cap
- 1.10B
- Vol
- 627.38K
- Avg vol
- 624.75K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.85
- High
- 23.52
- Forward P/E
- 29.95
- Beta
- 1.22
- Short ratio
- 6.21
- Inst. own
- 96.46%
- Dividend
- 0.00
- Ex-div date
- Dec 8, 2015
- Earnings
- Nov 5, 2026
- 50-d avg
- 23.98
- 200-d avg
- 29.49
- 1y target
- 40.91
News
3 days ago prnewswire.com
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming…
1 week ago prnewswire.com
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results…
-
1 week ago benzinga.com
Jefferies Initiates Coverage On Artivion with Buy Rating, Announces Price Target of $31
Jefferies analyst Michael Sarcone initiates coverage on Artivion (NYSE:AORT) with a Buy rating and announces Price Target of $31.
2 weeks ago benzinga.com
Transcript: Artivion Q2 2026 Earnings Conference Call
Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40
Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $39 to $40.
2 months ago marketbeat.com
Artivion Q2 Earnings Call Highlights
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines…
2 months ago seekingalpha.com
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
-
2 months ago benzinga.com
Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.
2 months ago prnewswire.com
Artivion Reports Second Quarter 2026 Financial Results
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis…
3 months ago prnewswire.com
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming…
3 months ago prnewswire.com
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial…
3 months ago defenseworld.net
Fifth Third Bancorp Buys 123,023 Shares of Artivion, Inc. $AORT
Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
4 months ago zacks.com
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
4 months ago seekingalpha.com
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion
Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major…
4 months ago benzinga.com
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.
-
4 months ago benzinga.com
Artivion Says FDA Approves Premarket Approval Application For AMDS Hybrid Prosthesis
Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket…
4 months ago prnewswire.com
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug…
4 months ago prnewswire.com
Artivion to Participate in the 2026 Truist Securities MedTech Conference
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming…
5 months ago gurufocus.com
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
5 months ago businesswire.com
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction…
5 months ago prnewswire.com
Artivion Completes Acquisition of Endospan Ltd.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing…
5 months ago fool.com
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
5 months ago prnewswire.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may…
5 months ago seekingalpha.com
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Artivion Q1 Earnings Call Highlights
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily…
5 months ago benzinga.com
Crude Oil Gains 1%; Fluor Shares Plunge After Q1 Results
US stocks traded higher, Nasdaq gained 1.5%. Dow down 0.06%. IT shares up 2.1% while healthcare stocks fell 0.9%. Fluor shares dropped 12% due to weak earnings. Westrock Coffee, Innodata, and Nlight…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on Artivion, Lowers Price Target to $48
Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and lowers the price target from $53 to $48.
5 months ago benzinga.com
Nasdaq Jumps 200 Points; US Adds 115,000 Jobs In April
US stocks rise as Nasdaq gains over 200 points, with tech leading. Nonfarm payrolls beat expectations but unemployment rate remains unchanged. Oil down 0.3%, gold up 0.8%, European and Asian markets…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
5 months ago benzinga.com
Needham Maintains Buy on Artivion, Lowers Price Target to $44
Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $58 to $44.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Artivion Lowers FY2026 Sales Guidance from $486.000M-$504.000M to $480.000M-$496.000M vs $495.284M Est
Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000 million-$496.000 million vs $495.284 million estimate.
-
5 months ago benzinga.com
Artivion Q1 Adj. EPS $0.08 Beats $0.05 Estimate, Sales $116.337M Beat $115.803M Estimate
Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 by 60 percent. This is a 33.33 percent increase over earnings of $0.06 per share…
6 months ago benzinga.com
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday
Dow Jones falls 250 points as UnitedHealth Group rises on Medicare reimbursement boost, other stocks also see gains in today's session.
8 months ago benzinga.com
Earnings Scheduled For February 12, 2026
Earnings Scheduled For February 12, 2026
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
Earnings Scheduled For February 24, 2025
Earnings Scheduled For February 24, 2025
-
2 years ago benzinga.com
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
-
2 years ago benzinga.com
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
-
2 years ago benzinga.com
'Most Suspicious Congressional Stock Trade?' Little-Known Med Tech Firm Surges 48% In Just 2 Months After Senator Tina Smith Bought The Dip
Sen. Tina Smith's (D-Minn.) controversial November investment yielded a 48% return within just two months.
-
2 years ago benzinga.com
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating…
-
3 years ago benzinga.com
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
-
3 years ago benzinga.com
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
-
3 years ago benzinga.com
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
-
3 years ago benzinga.com
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.